GHK-Cu copper peptide for smile lines: what TikTok skips

What did @kfruitfly actually say?

The claim is straightforward: a $7 Argireline 10% serum from The Ordinary "almost completely erased" her glabellar lines, known as 11s, over nine weeks. She also compared Argireline to Botox, saying Botox "severs the nerve to muscle receptor" while Argireline is more like "turning down the volume" on facial expressions. Those are specific, testable claims, not just vibes about glowing skin.

She deserves credit for the disclaimer work. She acknowledged the tan, the lighting consistency, and didn't claim the product works on deep, set-in wrinkles. That kind of self-aware framing is rare in this format. The before-and-after methodology is still weak by any scientific standard, but she's not pretending otherwise. She's saying: believe me or don't.

Does the science back this up?

Partially, yes. Argireline (acetyl hexapeptide-3) is a synthetic peptide that mimics the N-terminal end of SNAP-25, a protein involved in the SNARE complex that triggers neuromuscular signaling. In plain terms, it competes with a protein your nerve cells need to tell facial muscles to contract. Less contraction, less repeated skin folding, potentially fewer expression lines over time.

A 2002 study by Blanes-Mira et al. in the International Journal of Cosmetic Science showed Argireline reduced wrinkle depth by up to 30% in a 30-day trial. A 2013 follow-up by the same group found a liposome-encapsulated version improved delivery and efficacy. A 10% concentration is on the higher end of what's been studied topically, and The Ordinary's formulation is straightforward enough that the concentration is likely meaningful. However, most studies use controlled lab conditions, not someone's bathroom window, and effect sizes in real-world use are typically more modest than what the video shows.

What did they get wrong (or right)?

The Botox comparison is where things get shaky. She says Botox "severs the nerve to muscle receptor," which is not accurate. Botulinum toxin cleaves SNAP-25 inside the nerve terminal, blocking acetylcholine release. It doesn't sever anything structurally. The nerve-muscle connection remains intact; the signaling is temporarily blocked. It's a meaningful distinction because it explains why Botox is reversible and why comparing it to a topical peptide requires serious caveats.

The "turning down the volume" analogy for Argireline is actually reasonable as a loose metaphor. It competes with endogenous SNAP-25 at receptor sites rather than destroying the signaling machinery. But the magnitude of effect is incomparable. Botox achieves near-complete temporary paralysis of targeted muscles at clinical doses. Argireline at 10% topical achieves a fraction of that effect, if it penetrates adequately at all. Skin penetration of peptides this size remains a legitimate scientific debate (Gorouhi and Maibach, 2009, Skin Pharmacology and Physiology).

What should you actually know?

Argireline is a real peptide with real (if modest) evidence behind it. At $7, the risk-benefit math is easy. But three things matter here that the video glosses over.

• Skin penetration is the bottleneck. Peptides don't cross the skin barrier easily. The evidence for Argireline's topical efficacy comes largely from industry-funded studies or small trials. Independent replication is limited.
• Expression lines vs. static wrinkles is a real distinction, and she actually got this right. Argireline works on dynamic lines caused by repeated muscle movement. It won't touch lines that are already etched in at rest.
• Individual results vary enormously based on skin thickness, baseline muscle activity, application consistency, and hydration. A single creator's nine-week experience is not a clinical trial.
• The product is cosmetic, not drug-classified. That means no FDA review of efficacy claims. "Almost completely erased" is a personal observation, not a measured outcome.

If you want to try it, the risk is low. Just don't expect Botox results from a $7 bottle.